{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:24:56Z","timestamp":1790717096281,"version":"4.1.0"},"reference-count":11,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Blood & Cancer"],"published-print":{"date-parts":[[2022,8]]},"abstract":"Abstract<\/jats:title>Background<\/jats:title>Blinatumomab, a CD3\/CD19 BiTE\u00ae<\/jats:sup> (bispecific T cell engager) molecule, was superior to high\u2010risk third course consolidation chemotherapy (HC3) in prolonging event\u2010free survival (EFS) in children with high\u2010risk first relapse B\u2010cell precursor acute lymphoblastic leukemia (B\u2010ALL). Here, we report results from a post hoc measurable residual disease (MRD) analysis of this phase 3 study (NCT02393859).<\/jats:p><\/jats:sec>Procedure<\/jats:title>Children\u00a0>28 days and\u00a0<18 years with high\u2010risk first\u2010relapse B\u2010ALL in cytomorphological complete remission (M1 marrow,\u00a0<5% blasts) or with M2 marrow (\u22655% and\u00a0<25% blasts) after induction and two cycles of high\u2010risk consolidation chemotherapy (baseline) were enrolled in this trial. Patients received one cycle of blinatumomab (15 \u03bcg\/m2<\/jats:sup>\/day, 4\u00a0weeks, continuous intravenous infusion) or HC3. The primary endpoint was EFS. In this post hoc analysis, patients with MRD\u00a0<10\u20134<\/jats:sup> by PCR were grouped as having positive but not quantifiable (pbnq) or undetectable disease.<\/jats:p><\/jats:sec>Results<\/jats:title>A higher proportion of patients with MRD\u00a0<10\u20134<\/jats:sup> had undetectable versus pbnq disease after blinatumomab (day 29) than after HC3 (p<\/jats:italic>\u00a0=\u00a00.0367). Of the 22 patients with MRD \u226510\u20134<\/jats:sup> at baseline who achieved MRD remission after blinatumomab, 20 (91%) achieved MRD\u00a0<10\u20134<\/jats:sup> remission by day 15. Patients treated with blinatumomab had improved EFS and overall survival compared with those treated with HC3 independent of end\u2010of\u2010induction or baseline (end\u2010of\u2010second consolidation) MRD levels.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>Blinatumomab was more efficacious than HC3 regardless of MRD status before treatment. These data support the role of blinatumomab in inducing deep MRD remission, negating the poor prognostic value of MRD.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.29715","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T17:00:48Z","timestamp":1651165248000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high\u2010risk first relapse B\u2010cell precursor acute lymphoblastic leukemia"],"prefix":"10.1002","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7976-3654","authenticated-orcid":false,"given":"Franco","family":"Locatelli","sequence":"first","affiliation":[{"name":"IRCCS Ospedale Pediatrico Bambino Ges\u00f9 and Sapienza University of Rome Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1039-2872","authenticated-orcid":false,"given":"Cornelia","family":"Eckert","sequence":"additional","affiliation":[{"name":"Charite\u2013Universitatsmedizin Berlin Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ondrej","family":"Hrusak","sequence":"additional","affiliation":[{"name":"Charles University, Motol University Hospital Prague Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Buldini","sequence":"additional","affiliation":[{"name":"Maternal and Child Health Department University of Padua Padua Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Sartor","sequence":"additional","affiliation":[{"name":"Westmead Hospital Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6879-2671","authenticated-orcid":false,"given":"Gerhard","family":"Zugmaier","sequence":"additional","affiliation":[{"name":"Amgen Research (Munich) GmbH Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zeng","sequence":"additional","affiliation":[{"name":"Amgen Inc. Thousand Oaks California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepali","family":"Pilankar","sequence":"additional","affiliation":[{"name":"IQVIA Mumbai India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Morris","sequence":"additional","affiliation":[{"name":"Amgen Inc. Thousand Oaks California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arend","family":"von Stackelberg","sequence":"additional","affiliation":[{"name":"Charite\u2013Universitatsmedizin Berlin Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,4,28]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.6065"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-798322"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0580"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-265884"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-409813"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.123"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.10004"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.11.010"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.0987"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00342-x"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806521"}],"container-title":["Pediatric Blood & Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.29715","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pbc.29715","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.29715","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T22:18:16Z","timestamp":1692829096000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.29715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,28]]},"references-count":11,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1002\/pbc.29715"],"URL":"https:\/\/doi.org\/10.1002\/pbc.29715","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,28]]},"assertion":[{"value":"2021-10-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e29715"}}